Shionogi & Co., Ltd. (SGIOY) Stock Price & Analysis
Shionogi & Co., Ltd. (SGIOY) — price $8.80 (-1.35%), as of the Oct 2, 2026 trading session; market cap $15.0B. Expected results Oct 26, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Shionogi & Co., Ltd. · SGIOY · Healthcare · Drug Manufacturers - Specialty & Generic
Shionogi & Co., Ltd. operates as a Japanese pharmaceutical enterprise, dedicated to the discovery, creation, manufacturing, and commercialization of a diverse array of medicines, diagnostic reagents, and medical equipment within Japan.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $8.80 | |
| Change on the day | -1.35% | |
| 52-week range | $7.65 – $12.00 | |
| Market capitalisation | $15.0B | |
| Price / earnings (trailing) | 8.93 | |
| Shares traded on the day | 2.1K | |
| Beta (volatility vs the S&P 500) | 0.03 | |
| Dividends per share (last 12 months) | $0.24 | |
| Dividend yield (last 12 months) | 2.74% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Chronological order, not a duration scale. The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Shionogi & Co. (SGIOY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the SGIOY film — every key number, told as a short cinematic story
~2 min · open the film
What is Shionogi & Co. (SGIOY), and what does it report?
Short answer · as of
Shionogi & Co., Ltd. operates as a Japanese pharmaceutical enterprise, dedicated to the discovery, creation, manufacturing, and commercialization of a diverse array of medicines, diagnostic reagents, and medical equipment within Japan. Healthcare / Drug Manufacturers Specialty & Generic SEC filing business address: 1-8, Doshomachi 3-Chome, Chuo-KU, Osaka, M0, 541-0045. It employs 6,223 people and is led by Isao Teshirogi. In Q1 FY2026 it reported revenue of $1.05B and net income of $627M. The market values it at $15.0B.
What do the latest results show for Shionogi & Co. (SGIOY)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $1.05B. Against analyst estimates the company has EPS beat 7 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.04B Aug 3, 2026
- Latest report · revenue estimate
- $970.69M Aug 3, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 3, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 3, 2026 | $1.04B | $970.69M | $0.3600 | $0.1800 |
| May 12, 2026 | $880.45M | $895.52M | $0.1800 | $0.1500 |
| Jan 30, 2026 | $957.60M | $848.42M | $0.2800 | $0.1920 |
| Oct 27, 2025 | $743.87M | $742.35M | $0.1800 | $0.1602 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $1.05B | $627M | $0.37 (diluted) |
| Q4 FY2025 | $896M | $303M | $0.18 (diluted) |
| Q3 FY2025 | $935M | $473M | $0.28 (diluted) |
| Q2 FY2025 | $717M | $280M | $0.16 (diluted) |
What are the financial strengths and risks for Shionogi & Co. (SGIOY)?
Short answer
The distress and quality screens read Altman Z 2.98 · Piotroski F 3. Trailing ratios: ROE 16.5% · ROA 9.9% · current ratio 1.14 · earnings yield 10.9% · free-cash-flow yield 8.3%.
What should you watch next at Shionogi & Co. (SGIOY)?
Short answer · as of
The next earnings report is expected on Oct 26, 2026. The number it tests is the $135.64 EPS analysts carry for it. Analyst estimates on file carry FY2027 revenue $712.26B · EPS 135.64 · 6 analysts.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How is Shionogi & Co. scored?
Research dated 2026-09-13.
Shionogi is classified with specialty and generic manufacturers, but its business is not a generic-volume proposition. It combines marketed infectious-disease medicines with diagnostic products, medical equipment and development programs spanning a wide range of therapeutic areas.
Compared with a narrower drugmaker, Shionogi carries a broader scientific agenda and a substantial recurring research burden. Consolidated gross profit, research spending and pipeline conversion therefore reveal more about its economics than the industry label alone.
SGIOY also offers an over-the-counter security tied to an Osaka-based Japanese operator. Its reported institutional footprint is sparse and the disclosed leading positions are limited, a distinction in the security’s ownership context rather than in the underlying medical portfolio.
| Company | Price | Market value | Score |
|---|---|---|---|
| $0.36 Oct 2, 2026 | $5.81B | — Model unavailable | |
| $42.90 Oct 2, 2026 | $14.9B | — Model unavailable | |
| $85.00 Oct 2, 2026 | $10.0B | — Model unavailable | |
| $1.11 Oct 2, 2026 | $12.7B | — Model unavailable | |
| $22.14 Date unavailable | $11.1B | — Model unavailable | |
| $17.60 Date unavailable | $20.5B | — Model unavailable | |
| $12.25 Date unavailable | $10.2B | — Model unavailable | |
| $69.69 Date unavailable | $29.2B | — Model unavailable | |
| $99.96 Date unavailable | $6.51B | — Model unavailable | |
| $20.30 Date unavailable | $6.48B | — Model unavailable | |
| $8.80 Date unavailable | $38.8B | — Model unavailable | |
| $39.53 Date unavailable | $46.0B | — Model unavailable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $712.26B
- EPS estimate
- $135.64
Measured against a quoted price of $8.80 (as of Oct 2, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 0.0% Period end Jun 30, 2026
- Previous quarter · ownership
- 0.0% Prior to period end Jun 30, 2026
- Reporting holders
- 8 Period end Jun 30, 2026
- Previous quarter · holders
- 9 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Rhumbline Advisers | 82,033 |
| Sterling Capital Management LLC | 53,169 |
| Hourglass Capital, LLC | 43,900 |
| Gamma Investing LLC | 15,545 |
| Pnc Financial Services Group, INC. | 11,736 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Shionogi & Co. (SGIOY)?
What Investors Ask About Shionogi & Co. (SGIOY) — Healthcare
These answers are editorial: 1 of these 8 answers is drawn from the SGIOY research dossier (written Mar 18, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is SGIOY a good stock to buy?
Stock Expert AI does not rate SGIOY buy, sell or hold. Shionogi & Co., Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the SGIOY stock price today?
The last price recorded on this page for Shionogi & Co., Ltd. (SGIOY) is $8.80, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Shionogi & Co., Ltd. do?
Shionogi & Co., Ltd. is a research-driven pharmaceutical company focused on developing and commercializing innovative medicines. The company's core business involves the discovery, development, manufacture, and marketing of pharmaceutical products, diagnostic reagents, and medical devices.
What are the key factors to evaluate for SGIOY?
Evaluate SGIOY on fundamentals, analyst consensus, and risk factors. P/E: 8.93x. This expansion could be achieved through partnerships or direct investment in overseas operations. Not financial advice.
How frequently does SGIOY data refresh on this page?
SGIOY's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven SGIOY's recent stock price performance?
Shionogi & Co., Ltd. (SGIOY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong pipeline of drugs in development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SGIOY overvalued or undervalued right now?
Shionogi & Co., Ltd. (SGIOY) trades at 8.93x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SGIOY before investing?
Before investing in Shionogi & Co., Ltd. (SGIOY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (53 figures)
The 53 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 1-8, Doshomachi 3-Chome, Chuo-KU, Osaka, M0, 541-0045 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Park Tower, Kita, OS, 530-0011, JP". |
FMP — 40 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $8.80 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T02:04:28.064Z. | |
px.change | Change on the day | -1.35% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $15.0B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T02:04:26.225Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Oct 26, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Shionogi & Co., Ltd. operates as a Japanese pharmaceutical enterprise, dedicated to the discovery, creation, manufacturing, and commercialization of a diverse array of medicines, diagnostic reagents, and medical equipment within Japan. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$0.12 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 8.93 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 2.1K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.03 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers Specialty & Generic | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 8880 — American Depositary Receipts. | |
id.employees | Employees | 6,223 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Isao Teshirogi | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q1 FY2026 | $1.05B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q1 FY2026 | $627M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-08-03.revenue_actual | Revenue · reported — report date 2026-08-03 | $1.04B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-03.revenue_estimated | Revenue · estimate — report date 2026-08-03 | $970.69M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-03.eps_actual | EPS · reported — report date 2026-08-03 | $0.3600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-03.eps_estimated | EPS · estimate — report date 2026-08-03 | $0.1800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.revenue_actual | Revenue · reported — report date 2026-05-12 | $880.45M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.revenue_estimated | Revenue · estimate — report date 2026-05-12 | $895.52M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.eps_actual | EPS · reported — report date 2026-05-12 | $0.1800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.eps_estimated | EPS · estimate — report date 2026-05-12 | $0.1500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-30.revenue_actual | Revenue · reported — report date 2026-01-30 | $957.60M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-30.revenue_estimated | Revenue · estimate — report date 2026-01-30 | $848.42M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-30.eps_actual | EPS · reported — report date 2026-01-30 | $0.2800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-30.eps_estimated | EPS · estimate — report date 2026-01-30 | $0.1920 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-27.revenue_actual | Revenue · reported — report date 2025-10-27 | $743.87M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-27.revenue_estimated | Revenue · estimate — report date 2025-10-27 | $742.35M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-27.eps_actual | EPS · reported — report date 2025-10-27 | $0.1800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-27.eps_estimated | EPS · estimate — report date 2025-10-27 | $0.1602 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.institutions.depth.ownership_pct | Institutional ownership | 0.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 0.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 8 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 9 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Rhumbline Advisers — shares in provider snapshot | 82,033 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Sterling Capital Management LLC — shares in provider snapshot | 53,169 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Hourglass Capital, LLC — shares in provider snapshot | 43,900 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Gamma Investing LLC — shares in provider snapshot | 15,545 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Pnc Financial Services Group, INC. — shares in provider snapshot | 11,736 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 7 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $7.65 – $12.00 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 7 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-03 | |
fin.scores | Distress and quality screens | Altman Z 2.98 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 16.5% · ROA 9.9% · current ratio 1.14 · earnings yield 10.9% · free-cash-flow yield 8.3% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.est_eps | EPS estimate, FY2027 | $135.64 | UNRECORDED | Stored analyst estimates — Captured 2026-10-04 · Expired observation | |
earn.estimates | Analyst estimates, next fiscal year | FY2027 revenue $712.26B · EPS 135.64 · 6 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-10-04 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2027 | $712.26B | UNRECORDED | Stored analyst estimates — Captured 2026-10-04 · Expired observation |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.24 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 2.74% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-03.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($1.04B) with the recorded estimate ($970.69M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-03.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.3600) with the recorded estimate ($0.1800) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-03. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-03.revenue_actual,earn.history.depth.2026-08-03.revenue_estimated,earn.history.depth.2026-08-03.revenue_actual.comparison,earn.history.depth.2026-08-03.eps_actual.comparison,earn.history.depth.2026-08-03.eps_actual,earn.history.depth.2026-08-03.eps_estimated,earn.history.depth.2026-05-12.revenue_actual,earn.history.depth.2026-05-12.revenue_estimated,earn.history.depth.2026-05-12.eps_actual,earn.history.depth.2026-05-12.eps_estimated,earn.history.depth.2026-01-30.revenue_actual,earn.history.depth.2026-01-30.revenue_estimated,earn.history.depth.2026-01-30.eps_actual,earn.history.depth.2026-01-30.eps_estimated,earn.history.depth.2025-10-27.revenue_actual,earn.history.depth.2025-10-27.revenue_estimated,earn.history.depth.2025-10-27.eps_actual,earn.history.depth.2025-10-27.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers - Specialty & Generic The company's SEC filings classify it under SIC 8880 — American Depositary Receipts. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Business description | Shionogi & Co., Ltd. operates as a Japanese pharmaceutical enterprise, dedicated to the discovery, creation, manufacturing, and commercialization of a diverse array of medicines, diagnostic reagents, and medical equipment within Japan. The firm markets several key therapeutic agents, including Fetroja, a crucial therapy for multi-drug resistant gram-negative bacterial infections; Xofluza, an antiviral medication for influenza; and Tivicay, an effective anti-HIV agent. Shionogi also maintains an extensive research and development pipeline, with numerous compounds under investigation for various conditions. Its development portfolio includes treatments for opioid-induced constipation (Symproic), various pain types such as inflammatory pain (S-120083), neuropathic pain (S-010887, sivopixant), and neuropathic low back pain (S-637880). Sivopixant is additionally being explored for sleep apnea syndrome and refractory/unexplained chronic cough. In neuroscience, the company is advancing S-117957 for insomnia, Zuranolone for depression, SDT-001 for attention-deficit/hyperactivity disorder, and BPN14770 for Fragile X syndrome and Alzheimer's disease. Furthermore, it is developing S-237648 and S-309309 as potential obesity treatments. In oncology and hepatology, ADR-001 addresses decompensated liver cirrhosis, and S-723595 targets NASH. Multiple anti-cancer compounds are in development, including S-588410 for esophageal and bladder cancer, S-488210 for head and neck squamous cell carcinoma, S-588210 and S-531011 for solid tumors, and S-222611 for malignant tumors. Other experimental therapies include S-770108 for idiopathic pulmonary fibrosis, SR-0379 for cutaneous ulcers, S-005151 for stroke and epidermolysis bullosa, and S-0373 for spinocerebellar ataxia. Addressing the ongoing pandemic, Shionogi is also advancing S-600918 and S-217622 for COVID-19, with S-555739 specifically aimed at preventing the aggravation of the disease. Beyond therapeutics, it supplies antibody test kits for COVID-19. The organization has established collaborative agreements with institutions like Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to further the development of antimalarial drugs. Founded in 1878, the company was initially known as Shionogi Shoten Co., Ltd. before adopting its current designation, Shionogi & Co., Ltd., in 1943. Its corporate operations are based in Osaka, Japan. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Ticker / exchange | SGIOY on Other OTC | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Headquarters | 1-8, DOSHOMACHI 3-CHOME, CHUO-KU, OSAKA, M0, 541-0045 Our market-data provider lists "Park Tower, Kita, OS, 530-0011, JP"; the address on file with the SEC is used here. | 2026-09-13 | OFFICIAL | SEC EDGAR filer business address |
| Institutional ownership (13F) | Holders: 8; Quarter: 2026-06-30; Ownership: 0%; Holders previous quarter: 9; Ownership previous quarter: 0 13F filings are quarterly and lag the quarter end by up to 45 days. | 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings |
| Largest 5 institutional holders | Captured record · 5 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings |
Data provided for informational purposes only.